
Ned Sacktor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/167263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	3.7	1
2	Evaluation of a screening tool for the identification of neurological disorders in rural Uganda. Journal of the Neurological Sciences, 2021, 421, 117273.	0.3	1
3	Assessment, prevalence, and correlates of frailty among middle-aged adults with HIV in rural Uganda. Journal of NeuroVirology, 2021, 27, 487-492.	1.0	2
4	Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda. Brain, Behavior, and Immunity, 2021, 93, 111-118.	2.0	9
5	Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda. Journal of NeuroVirology, 2021, 27, 519-530.	1.0	1
6	Brain structural correlates of trajectories to cognitive impairment in men with and without HIV disease. Brain Imaging and Behavior, 2020, 14, 821-829.	1.1	13
7	Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1–Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. Clinical Infectious Diseases, 2020, 71, 158-165.	2.9	10
8	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.2	15
9	The Veterans Aging Cohort Study Index is not associated with HIV-associated neurocognitive disorders in Uganda. Journal of NeuroVirology, 2020, 26, 252-256.	1.0	3
10	Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research. Journal of NeuroVirology, 2020, 26, 809-823.	1.0	19
11	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	1.7	12
12	Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 278-283.	0.9	4
13	Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals. Journal of NeuroVirology, 2020, 26, 382-390.	1.0	15
14	Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 534-542.	0.9	8
15	Neurocognitive Complications of HIV Infection in Low-Income Countries. Current Topics in Behavioral Neurosciences, 2019, 50, 225-244.	0.8	0
16	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	2.1	15
17	Letter to the Editor. Journal of NeuroVirology, 2019, 25, 897-898.	1.0	0
18	Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 800-813.	1.0	14

#	Article	IF	CITATIONS
19	Vitamin D is not associated with HIV-associated neurocognitive disorder in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 410-414.	1.0	5
20	Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study. Neurology, 2019, 93, e261-e271.	1.5	28
21	Interleukin-6 is associated with mortality and neuropsychiatric outcomes in antiretroviral-naÃ ⁻ ve adults in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 735-740.	1.0	11
22	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.2	28
23	Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology, 2019, 92, e1344-e1353.	1.5	9
24	Association of Marijuana Use with Changes in Cognitive Processing Speed and Flexibility for 17 Years in HIV-Seropositive and HIV-Seronegative Men. Substance Use and Misuse, 2019, 54, 525-537.	0.7	15
25	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	1.0	44
26	Cross-sectional analysis of cognitive function using multivariate normative comparisons in men with HIV disease. Aids, 2019, 33, 2115-2124.	1.0	19
27	Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. Aids, 2019, 33, S145-S157.	1.0	85
28	Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 216-223.	0.9	21
29	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	1.0	35
30	Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 61-70.	0.9	18
31	Neuropsychological changes in efavirenz switch regimens. Aids, 2019, 33, 1307-1314.	1.0	7
32	Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda. Journal of NeuroVirology, 2019, 25, 248-253.	1.0	8
33	Caregiver versus self-reported activities of daily living among HIV-positive persons in Rakai, Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 836-839.	0.6	2
34	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	1.0	77
35	7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests. American Journal of Neuroradiology, 2018, 39, 704-712.	1.2	13
36	Changing clinical phenotypes of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2018, 24, 141-145.	1.0	83

#	Article	IF	CITATIONS
37	Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. Journal of NeuroVirology, 2018, 24, 16-27.	1.0	34
38	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.2	29
39	Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. Aids, 2018, 32, 1679-1688.	1.0	14
40	HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition. Aids, 2018, 32, 1803-1810.	1.0	27
41	Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy. Aids, 2018, 32, 1661-1667.	1.0	60
42	Intraindividual variability in neurocognitive performance: No influence due to HIV status or self-reported effort. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 1044-1049.	0.8	3
43	Differences in Cognitive Function Between Women and Men With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 101-107.	0.9	70
44	Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. Aids, 2017, 31, 1365-1378.	1.0	8
45	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
46	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375.	1.0	46
47	Visceral fat is associated with brain structure independent of human immunodeficiency virus infection status. Journal of NeuroVirology, 2017, 23, 385-393.	1.0	16
48	The BIOCARD Index. Alzheimer Disease and Associated Disorders, 2017, 31, 114-119.	0.6	6
49	Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda. Neurology, 2017, 89, 485-491.	1.5	36
50	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic―versus "asymptomatic―HAND. Journal of NeuroVirology, 2017, 23, 67	7-78.	25
51	Association of midlife smoking status with change in processing speed and mental flexibility among HIV-seropositive and HIV-seronegative older men: the Multicenter AIDS Cohort Study. Journal of NeuroVirology, 2017, 23, 239-249.	1.0	2
52	Cognitive Impairment Among Older Individuals with HIV Infection. Current Geriatrics Reports, 2016, 5, 63-70.	1.1	7
53	Reward, attention, and HIV-related risk in HIV+ individuals. Neurobiology of Disease, 2016, 92, 157-165.	2.1	34
54	HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment. Nature Reviews Neurology, 2016, 12, 234-248.	4.9	690

#	Article	IF	CITATIONS
55	Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology, 2016, 86, 334-340.	1.5	293
56	Cortical brain atrophy and intra-individual variability in neuropsychological test performance in HIV disease. Brain Imaging and Behavior, 2016, 10, 640-651.	1.1	34
57	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Journal of Virus Eradication, 2016, 2, 243-250.	0.3	22
58	Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. International Journal of Epidemiology, 2015, 44, 1506-1516.	0.9	58
59	Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study. Aids, 2015, 29, 713-721.	1.0	24
60	Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. Journal of NeuroVirology, 2014, 20, 620-626.	1.0	24
61	Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 517-520.	1.5	57
62	HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metabolic Brain Disease, 2014, 29, 261-268.	1.4	21
63	Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda. Journal of NeuroVirology, 2013, 19, 48-56.	1.0	28
64	A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. Journal of NeuroVirology, 2013, 19, 432-441.	1.0	17
65	Older individuals with HIV infection have greater memory deficits than younger individuals. Journal of NeuroVirology, 2013, 19, 531-536.	1.0	27
66	A lipid storage–like disorder contributes to cognitive decline in HIV-infected subjects. Neurology, 2013, 81, 1492-1499.	1.5	53
67	Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 696-703.	1.3	114
68	CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder. Current Biomarker Findings, 2012, 2012, 1.	0.4	5
69	Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology, 2012, 54, 113-121.	1.1	117
70	A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2011, 17, 159-165.	1.0	46
71	Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 382-392.	1.0	40
72	Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging and Behavior, 2011, 5, 77-85.	1.1	154

#	Article	IF	CITATIONS
73	Longitudinal psychomotor speed performance in human immunodeficiency virus–seropositive individuals: impact of age and serostatus. Journal of NeuroVirology, 2010, 16, 335-341.	1.0	44
74	Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection. Journal of NeuroVirology, 2010, 16, 368-376.	1.0	13
75	Human immunodeficiency virusâ€ a ssociated neurocognitive disorders: Mind the gap. Annals of Neurology, 2010, 67, 699-714.	2.8	382
76	Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Therapy, 2010, 4, 371-379.	0.6	33
77	Factor Analysis of Proton MR Spectroscopic Imaging Data in HIV Infection: Metabolite-derived Factors Help Identify Infection and Dementia. Radiology, 2010, 254, 577-586.	3.6	36
78	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. Clinical Infectious Diseases, 2009, 49, 780-786.	2.9	129
79	Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. Journal of NeuroVirology, 2008, 14, 362-367.	1.0	66
80	Human Immunodeficiency Virusâ€Associated Dementia: Clinical Aspects, Biology, and Treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 799-806.	1.0	0
81	Evolution of HIV dementia with HIV infection. International Review of Psychiatry, 2008, 20, 25-31.	1.4	111
82	Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Future HIV Therapy, 2008, 2, 271-280.	0.5	31
83	Platelet Decline. Archives of Neurology, 2007, 64, 1264.	4.9	37
84	HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nature Clinical Practice Neurology, 2007, 3, 436-443.	2.7	49
85	Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurology, 2007, 7, 8.	0.8	69
86	Neuropsychological test profile differences between young and old human immunodeficiency virus–positive individuals. Journal of NeuroVirology, 2007, 13, 203-209.	1.0	85
87	Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Current Opinion in Neurology, 2006, 19, 358-361.	1.8	94
88	Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii Aging with HIV Cohort. Journal of NeuroVirology, 2006, 12, 387-391.	1.0	102
89	Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: Protection by diosgenin and I-deprenyl. Neurobiology of Disease, 2006, 23, 109-119.	2.1	74
90	Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Annals of Neurology, 2006, 59, 237-247.	2.8	91

#	Article	IF	CITATIONS
91	A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. Journal of Magnetic Resonance Imaging, 2005, 21, 325-333.	1.9	51
92	The International HIV Dementia Scale: a new rapid screening test for HIV dementia. Aids, 2005, 19, 1367-74.	1.0	282
93	Novel markers of oxidative stress in actively progressive HIV dementia. Journal of Neuroimmunology, 2004, 157, 176-184.	1.1	83
94	Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy. Archives of Neurology, 2004, 61, 1687.	4.9	125
95	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	1.0	370
96	Neuroprotective Therapy for HIV Dementia. Current HIV Research, 2003, 1, 373-383.	0.2	39
97	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	1.0	22
98	The Epidemiology of Human Immunodeficiency Virus-Associated Neurological Disease in the Era of Highly Active Antiretroviral Therapy. Journal of NeuroVirology, 2002, 8, 115-121.	1.0	354
99	HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of NeuroVirology, 2002, 8, 136-142.	1.0	555